The patent for the original research drug has not yet expired, but the raw material drug company has already tasted sweetness before the generic drug.
Recently, Fang Hongjun, deputy general manager of Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianyu Pharmaceutical") told the "First Financial Daily" that benefiting from the expiration of the Novartis Pharmaceuticals Valsartan patent due in 2012, etc., This year, the company's sales of raw materials for Sartan increased by a substantial 60%, annual sales were expected to reach 1 billion yuan, and net profits exceeded 100 million yuan.
Tianyu Pharmaceuticals and Huahai Pharmaceuticals are the two domestic producers of raw materials for satanic drugs (a kind of antihypertensive drugs) with the largest production capacity. The products are mainly used for export. According to the third quarterly report of Huahai Pharmaceutical, during the period, the company obtained a net profit of approximately RMB 60 million, an increase of 109% over the same period of the previous year, which was mainly due to the rapid growth of sales of Shatan products and the recognition of income from real estate projects.
Sartan drugs are classic antihypertensive drugs. In 2011, the domestic Sartan drugs market had reached a scale of 4.5 billion yuan, accounting for 33.17% of the antihypertensive drug market, an increase of more than 17% year-on-year. With the market share of 27.51% of Valsartan and the occupancy rate of 14.21% of the irbesart patent will expire in 2012, the corresponding characteristics of raw material drugs usher in a rapid increase.
Mr. Sun, a pharmaceutical analyst with a brokerage in Shanghai, told reporters that in the two or three years prior to the expiration of the patent, companies interested in entering generic drugs will begin to purchase bulk drugs on a large scale, one for R&D and pilot production, and the other Accumulated inventory for post-production. The data show that in 2010, the production of five main sandtan varieties, including losartan potassium, valsartan and telmisartan, was 332.76 tons, an increase of 159.4% over the previous year.
Informed sources revealed that Tianyu Pharmaceutical has entered the mentoring period of the securities companies and plans to list on the A-shares next year. The raised funds will be used for the expansion of Shatan's products. Fang Hongjun said that the company currently has a GMP production certificate for losartan, valsartan and irbesartan bulk drugs, and is applying for a GMP certificate for raw material drugs of candesartan and olmesartan.
The same trend has also emerged in other areas. Pfizer's celebrity drug atorvastatin (Lipitor) has expired on November 30 this year and domestic pharmaceutical companies are investing in the production of atorvastatin API. Mr. Zou, a research and development engineer for a fermented drug company, told reporters that the company had signed a cooperation agreement with argentinstatin for the production of bulk drugs and several domestic pharmaceutical companies.
“The pattern of production of raw materials with domestic characteristics has taken shape. Enterprises in Zhejiang Xinchang and Taizhou, such as Hisun Pharmaceutical and Huahai Pharmaceutical, have developed specialty raw materials and further developed them to the downstream products.†Mr. Sun believes. The reporter was informed that raw material companies such as Jiuzhou Pharmaceutical and Xindonggang Pharmaceutical in Xinchang District of Zhejiang Province are all seeking listing and financing to rapidly expand their production capacity.
Haizheng Pharmaceuticals and Huahai Pharmaceuticals, which have taken the first step in expansion, are actively expanding the export of pharmaceutical preparations in order to meet the government's industrial upgrading strategy while expanding the production capacity of raw materials.
Silica Sol Investment Casting,Silica Sol Casting Part,Machining Silica Casting Parts,Custom Silica Casting Parts
Wuxi Sixleaf Machinery Co. LTD , https://www.wuxisixleafmachine.com